Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional ) | PAR 18 509

Opportunity Information: Apply for PAR 18 509

The National Institutes of Health (NIH) funding opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional)" (Funding Opportunity Number PAR 18 509) is a discretionary grant program designed to support exploratory, early-stage research on synthetic psychoactive drugs. Using the NIH R21 mechanism, it aims to generate new, potentially high-impact knowledge about how these substances are used, how they work in the body and brain, what kinds of short- and long-term health harms they cause, and which practical strategies can prevent harm or improve clinical care. The "clinical trial optional" designation means applicants may propose projects that include clinical trials, but they are not required to do so; the FOA can support both clinical and non-clinical studies as long as they align with the overall purpose.

At its core, the FOA is focused on improving the evidence base around synthetic psychoactive substances, a category that can include rapidly evolving drug products that may be marketed as legal alternatives to controlled substances, sold online, or appear in illicit markets with shifting formulations. Because these drugs can change quickly and may have unpredictable potency or composition, the opportunity emphasizes research that clarifies mechanisms of action (for example, how a compound interacts with receptors, neurotransmitter systems, or other biological targets), patterns of use (who uses these substances, how they are obtained, and what contexts increase risk), and resulting health effects. The health-effects emphasis includes acute harms that often drive emergency department visits (such as agitation, psychosis, cardiovascular complications, seizures, respiratory depression, hyperthermia, or other toxic presentations depending on the substance) as well as longer-range impacts that may involve dependency, mental health consequences, cognitive effects, and broader functional outcomes.

A major theme is translating scientific insight into real-world strategies that reduce harm. That includes prevention approaches, which could range from targeted education and risk communication to community-based interventions, screening approaches, or other methods that measurably reduce initiation or dangerous patterns of use. It also includes strategies to treat patients in emergency departments, where clinicians may face uncertain diagnoses and limited information about what a patient took. Projects responsive to this FOA can therefore involve work that improves recognition and management of acute intoxication, supports development or evaluation of clinical protocols, or strengthens the pipeline from toxicology and pharmacology knowledge into practical bedside decision-making. In addition to acute care, the FOA explicitly calls for strategies supporting longer-range treatment, meaning research that informs follow-up care, treatment engagement, relapse prevention, and recovery outcomes after the immediate crisis has passed.

From an administrative standpoint, this is a grant (FundingInstrumentType: Grant) in the Education and Health activity category, listed under CFDA 93.279. The award ceiling is stated as 200,000, indicating the maximum funding amount anticipated per award under this opportunity. The FOA was created on 2017-12-18, and the original closing date provided in the source data is 2020-05-07. The listing shows "ExpectedAwards:" without a number, meaning the count of expected awards is not specified in the provided details and may vary by year, budget availability, and application quality.

Eligibility is broad and includes many types of applicants that can contribute to research and implementation in this area. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized); public housing authorities and Indian housing authorities; Native American tribal organizations (other than federally recognized tribal governments); nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities. The FOA also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal government agencies, regional organizations, U.S. territories or possessions, tribal governments that are not federally recognized, and non-U.S. entities (foreign organizations). Taken together, that eligibility profile signals NIH interest in supporting a wide range of scientific, clinical, and community-based perspectives, including organizations positioned to reach populations disproportionately affected by emerging synthetic drugs.

In practical terms, the FOA is best understood as support for innovative, shorter-horizon R21 projects that can either open up new lines of research (for example, identifying novel mechanisms or high-risk use patterns) or test promising prevention and treatment approaches in ways that can later be scaled or followed by larger studies. The overarching expectation is that funded projects will strengthen understanding of synthetic psychoactive drugs and lead to actionable strategies that reduce medical harm, improve emergency response, and support sustained treatment and recovery.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional )" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2017-12-18.
• Applicants must submit their applications by 2020-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 509

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: